• CSL entered an exclusive global collaboration with Alentis to jointly develop, co-promote, and commercialize lixudebart for rare kidney and liver diseases.
• CSL will pay Alentis USD 355 million upfront, with up to USD 1.2 billion tied to commercial milestones.
• CSL will fully fund the ongoing Phase 2 RENAL trial, a planned Phase 3 program in AAV-RPGN, and Phase 2 studies in FSGS and PSC.
• Global profits will be split 55% to CSL, 45% to Alentis once lixudebart is commercialized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050825PR_NEWS_EUPR__ES_SE63268) on October 05, 2026, and is solely responsible for the information contained therein.